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Abstract
Background: The trigeminal ganglion (TG) plays a central role in cranial pain. Administration of complete Freund’s
adjuvant (CFA) into the temporomandibular joint (TMJ) elicits activation of TG. Kynurenic acid (KYNA) is an
endogenous excitatory amino acid receptor blocker, which may have an anti-inflammatory effect. We hypothesize
that KYNA may reduce CFA-induced activation within the TG.
Methods: A local inflammation was induced by administration of CFA into the TMJ in rats. KYNA and kynurenic
acid amide 2 (KYNAA2) were intraperitoneally administered. We investigated changes of mitogen-activated protein
kinases (MAPKs as ERK1/2, p38 and SAPK/JNK), NF-κB, CaMKII and DREAM, in addition to calcitonin gene-related
peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity-modifying
protein 1 (RAMP1) in the TG, with immunohistochemistry and Western blot at 2 and 10 days post-CFA injection.
Results: We showed CFA-induces increases in pERK1/2, pp38, CaMKII, NF-κB and DREAM immunohistochemistry
after 2 and 10 days. KYNAA2 displayed stronger effects on MAPKs than KYNA. Increased expression of CaMKII, NF-κB
and DREAM were found in the neurons. Western blot showed significantly increase in pERK expression at 10 days
post-CFA, which decreased after 10 days of KYNA treatment. Two days post-CFA, a significantly increase in pp38
expression was found, which decreased after 2 days of KYNA and KYNAA2 treatment.
Conclusions: The CFA-induced inflammatory model for the TG activation provided a time-related expression of
MAPK (pERK1/2, pp38) and NF-κB. It involves both the neuronal and glial activation, which points to possible
neuron-glia interactions during this process. The administration of the endogenous NMDA-receptor antagonists,
KYNA and its derivative KYNAA2, resulted in the inhibition of the induced signaling system of the TG, which further
points the importance of the glutamate receptors in this mechanism.
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Cell signaling pathways
Background
The trigeminal ganglion (TG) through the mandibular
branch (V3) of the trigeminal nerve projects sensory
innervation to the temporomandibular joint (TMJ)
capsule. TG contains mainly two populations of cells:
neurons of different size and satellite glial cells (SGCs).
The neurons project both in central and peripheral direc-
tion with unmyelinated C-fibers and thinly myelinated
Aδ-fibers to transmit sensory information of different mo-
dalities. The functional importance of SGCs in sensory
ganglia is less well understood, but neuron-glia interaction
is presumed as the SGCs may process and transmit chem-
ical signals, and regulate their microenvironment [1–3].
Numerous studies have used chemical stimulation
of peripheral nerve branches with Complete Freund’s
adjuvant (CFA) as an inflammatory model for investi-
gating changes in the levels of various messenger and
mediator molecules within the TG and in the CNS
after experimentally induced TMJ inflammation [4–6].
It has been shown that the mitogen-activated protein
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kinase (MAPK) system can be activated by local appli-
cation of CFA [7–9]. The MAPKs, a family of serine/
threonine kinases, are involved in cellular responses to
external signals such as pain [10, 11], growth factors,
stress and inflammatory mediators [12–15]. The three
major MAPKs are p38, extracellular signal-regulated kinase
1/2 (ERK1/2) and stress-activated protein kinase/c-jun N-
terminal kinase (SAPK/JNK). These are located at the
end of a dynamic chain of kinases [16] and are able
to phosphorylate several downstream targets. The ini-
tial stimulus for this cascade varies between the
MAPKs. ERK1/2 is often activated by growth factors
[12], while p38 and SAPK/JNK are stress-activated
protein kinases, which respond to cellular stress and
inflammatory cytokines [14, 15, 17]. Activation of
MAPKs can result in e.g. apoptosis, differentiation
and proliferation [18].
Furthermore, it is well known that cytokines can acti-
vate different signaling pathways, including MAPKs [19].
Activation of MAPKs initiates the induction of nuclear
factor kappa B (NF-κB) [20, 21], a key factor in the
regulation of transcription of genes including inducible
nitric oxide (NO) synthase, cyclooxygenase-2, tumor
necrosis factor-α (TNF-α), interleukin-1β and
interleukin-6 [22, 23]. Moreover, calcium calmodulin-
dependent protein kinase II (CaMKII) plays a role in
nociception and pain transmission in the trigeminal
nucleus caudalis [24–26]. Intracellular calcium also
modulates the nuclear translocation of the downstream
regulatory element antagonist modulator (DREAM),
which plays a role in endogenous responses to pain
[27, 28]. DREAM −/− knock-out mice display reduced
pain behavior in models of acute thermal, mechanical
and visceral pain, and in chronic neuropathic and in-
flammatory pain [29].
Calcitonin gene-related peptide (CGRP) plays a key
role in migraine pathophysiology [30]. CGRP is stored in
TG small-medium sized neurons and its receptor com-
ponents calcitonin receptor-like receptor (CLR) and re-
ceptor activity-modifying protein 1 (RAMP1) in large
neurons and glial cells [31]. Upon activation of the TG,
CGRP is released. Blocking the CGRP signaling with
CGRP receptor antagonists has opened a possible option
in migraine treatment [32].
Kynurenic acid (KYNA), a metabolite of the kynure-
nine pathway is produced by astrocytes and neurons
[33]. It prevents neuronal loss following excitotoxic and
ischaemic induced neuronal injuries [34]. Previously it
has been shown that a series of kynurenic acid amines
were found to be N-metyl-D-aspartat (NMDA) receptor
NR2B subunit antagonists. In the study, a newly synthe-
sized KYNA analogue, kynurenic acid amide 2
(KYNAA2, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-
quinoline-2-carboxamide hydrochloride) was tested and
shown to have neuroprotective potential [35]. Further-
more, KYNA also acts on glutamatergic and nicotiner-
gic neurotransmission [36–40].
The aim of this study was to investigate the time-
related changes of the cell signaling pathways in the
TG following in vivo application of CFA into the TMJ.
Because glutamate is a co-transmitter in the trigeminal
system, we hypothesize that KYNA and derivative
KYNAA2 might inhibit intracellular signaling path-
ways during CFA induced activation.
Methods
Animals
Adult male Sprague–Dawley rats (200-300 g, n = 6 in
each group for immunohistochemistry and Western
blot) were used in the experiments. Animals were raised
and maintained under standard laboratory conditions.
The study followed the guidelines of the European
Communities Council (86/609/ECC) and approved by
the Ethics Committee of The Faculty of Medicine,
University of Szeged (I-74-12/2012, XI./352/2012).
The CFA injection was performed with the antero-
superior technique, established by Kameoka et al. [41],
into the right upper TMJ. Briefly, the TMJ region was
identified by palpation. A 27-gauge needle was advanced
into the TMJ space along the superomedial border of the
zygomatic arch until it reached the condyle. This
method of administration to the TMJ has been shown to
be very accurate according to arthrographic CT of the
joint, using contrast media [41].
The CFA injection (0.05 ml) consisted of 300 μg heat
killed and dried Mycobacterium tuberculosis, paraffin oil
and mannide monooleate [42], (Sigma-Aldrich, St. Louis,
MO, USA), diluted in saline (oil:saline 1:1), creating an
emulsion. One hour before CFA injection, the rats were
pretreated with KYNA (Sigma-Aldrich, St. Louis, MO,
USA) or the KYNAA2 in an equimolar, 300 mg/kg body-
weight dose (diluted to 2 ml, pH 7.4), intraperitoneally
[26, 43, 44]. KYNA and KYNAA2 treatments were then
carried out every 12 h for 48 h (termed 2 days post-
CFA injection). Zhou et al. [45] demonstrated that the
Fos protein, a marker of neuronal activation, peaked at
24–48 h after CFA injection into the TMJ. Conse-
quently, we chose 48 h as survival time in order to
evaluate the effect of the different treatments. In
addition, KYNA treatment was applied for 10 days
(termed 10 days post-CFA injection) to demonstrate
possible long-term effects.
The control inflammatory groups received only the
CFA injection and these rats were terminated at 2 and
10 days post-injection according to Zhou et al. [45].
Healthy, untreated rats were used as normal controls
(termed Fresh). Before TMJ injections animals were
deeply anaesthetized with chloral hydrate (0.4 g/kg
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bodyweight, Fluka Analytical, Buchs, Switzerland).
Healthy controls were also anaesthetized in the same
way.
For immunohistochemistry, the rats were transcar-
dially perfused with phosphate buffer for 5 min at a flow
rate of 10 ml/min, followed by perfusion with 4 % para-
formaldehyde in phosphate buffer for 20 min at the
same flow rate. TGs from the right side were then
dissected out, keeping the orientation of the three
branches V1, V2 and V3 of the trigeminal nerve (Fig. 1).
After overnight post-fixation, specimens were rinsed re-
peatedly in sucrose-enriched (10 %) Tyrode solution.
The ganglia were frozen on dry ice and stored at −80 °C.
The specimens were embedded in gelatin medium
(30 % egg albumin, 3 % gelatin in distilled water), cryo-
sectioned at 12 μm, mounted on Superfrost Plus
coated slides (Menzel GmbH Co KG, Braunschweig,
Germany) and stored at −20 °C until use.
For Western blot, TGs were harvested without fix-
ation and frozen in liquid nitrogen. They were stored
at −80 °C until use.
Hematoxylin-eosin staining
For orientation of the three branches (Fig. 1) and exam-
ination of morphology and tissue condition, the sections
were stained with Hematoxylin-Eosin (Htx-Eosin) using
a standard protocol (Htx 4 min, water rinse, Eosin 30 s).
Immunohistochemistry
Immunohistochemical demonstration of MAPKs
(pERK1/2, pp38, pSAPK/JNK), NF-κB, CaMKII and
DREAM was performed using indirect immunohisto-
chemistry. CGRP, a major molecule in migraine ther-
apy, and its receptor components CLR and RAMP1
were additionally immunohistochemically processed. More-
over, antibodies against inwardly rectifying potassium chan-
nel (Kir4.1, marker for glial cells) were used. Details of the
primary and secondary antibodies used are given in Tables 1
and 2.
Briefly, sections were rehydrated for 15 min in PBS
containing 0.25 % Triton X-100 (PBS-T, Chemicon,
Sweden). Sections were then exposed to primary antisera
in PBS-T containing 1 % bovine serum albumin (BSA)
overnight in a moist chamber at +4 °C. Thereafter, the
sections were rinsed (PBS-T for 2 × 15 min), followed by
incubation with secondary antibodies for 1 h in dark at
room temperature. Sections were then rinsed in PBS-T
for 3 × 10 min in room temperature and mounted with
Vectashield (Vector Laboratories, Burlingame, CA,
USA). Vectashield medium containing 4′, 6-diamino-2-
phenylindole (DAPI, nucleus staining) was used.
Kir4.1 and pp38 or pSAPK/JNK, pERK1/2 and CLR or
RAMP1, and NF-κB and CGRP double immunohisto-
chemistry was additionally performed. The same protocol
as described below was used during three consecutive
days. (1) Day one: application of Kir4.1 (host rabbit); (2)
Day two: application of secondary anti-rabbit antibodies
and thereafter pp38 (host mouse); (3) Day three: applica-
tion of secondary anti-mouse antibodies.
Omission of the primary antibody served as negative
controls.
Image analysis
Sections were examined and images were obtained using
a light- and epifluorescence microscope (Nikon 80i,
Tokyo, Japan) coupled to a Nikon DS-2 MV camera.
FITC (480/30X), TRITC (540/24X) and DAPI (360/
40X) filters were used (filter specifications are given in
nanometers and X denotes excitation center wave-
length/bandwidth). Adobe Photoshop CS3 (v.8.0,
Adobe Systems, Mountain View, CA, USA) was used
to visualize co-labeling by superimposing the digital
images.
Western blot
TG were homogenized in cell extract denaturing buffer
(BioSource, USA) containing phosphatase and protease
inhibitor cocktails (Sigma-Aldrich, Germany). After
centrifugation (12,000 rpm, 4 °C, 10 min) the supernatants
were collected. Protein concentrations were measured
with a protein assay reagent (Bio-Rad Laboratories,
Hercules, CA) and Tecan Infinite M200 microplate
reader. Protein samples were mixed with Laemmli Sample
Buffer (Bio-Rad Laboratories) and heated (95 °C, 4 min).
Equal amounts (40 μg) of protein were loaded onto
4–15 % Ready Gel Precast Gels (Bio-Rad Laboratories)
with a molecular weight marker (Precision Plus Protein
Standard, Bio-Rad Laboratories). Gel electrophoresis was
followed by blocking in 5 % non-fat milk or BSA and incu-
bation with primary antibodies (4 °C, overnight), then with
secondary antibodies (1 h, room temperature). Details of
Fig. 1 Schematic drawing of the rat head and the trigeminal
ganglion (TG). The three branches V1, V2 and V3 of the trigeminal
nerve are shown. Mainly the mandibular part (V3) of the TG
was investigated
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primary and secondary antibodies used are given in
Tables 1 and 2. β-actin was used as an internal loading
control. Finally, the membranes were incubated in en-
hanced chemiluminescent substrate (Pierce Protein
Research Product, Thermo Scientific, Germany) and
developed using KODAK light film and reagents
(Sigma-Aldrich, Germany). The band optical density
ratio was quantified using ImageJ software. Analysis of
variance followed by Bonferroni (IBM SPSS Statistics,
Version 20, 2011, Armonk, NY, USA) was used for
statistical analysis (*p ≤ 0.05, **p ≤ 0.005).
Results
Hematoxylin-eosin
Most TGs displayed qualitatively good morphology as visu-
alized with Htx-Eosin staining (Figs. 2a–f). Ganglia con-
sisted of neurons enveloped by SGCs. Minor cell shrinkage
was observed. In all TG following CFA injection into the
TMJ, sterile abscesses containing polymorphonuclear cells
and macrophages were observed (Fig. 2b–f). In addition,
perineurium thickening was found in the CFA groups.
Immunohistochemistry
The CFA induced inflammation showed main activation
in the third division (Fig. 1, mandibular branch) of the
TG, but some was also found in the rest of the ganglion.
In our study, we primarily examined the changes present
in the third division (data not shown).
pERK1/2
In fresh untreated TG, pERK1/2 immunoreactivity was
detected in nuclei, including nucleoli, of the trigeminal
neurons (Fig. 3a). In contrast, high-intensity pERK1/2 im-
munoreactivity was observed in SGCs at 2 days (Fig. 3b)
and at 10 days post-CFA injection in the TMJ (Fig. 3c). In
Table 1 Details of primary antibodies used for immunohistochemistry (IH) and Western blotting (WB)
Name Product code Host Dilution Source
IH WB
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 4376 Rabbit 1:50 1:1000 Cell Signaling Technology, Danvers, MA, USA
Phospho-p38 MAPK (Thr180/Tyr182) 9216 Mouse 1:400 1:2000 Cell Signaling Technology, Danvers, MA, USA
Phospho-SAPK/JNK (Thr183/Tyr185) 9255 Mouse 1:400 1:2000 Cell Signaling Technology, Danvers, MA, USA
Anti-NFκB p65 (phosphor S529) ab97726 Rabbit 1:100 1:1000 Abcam; Cambridge, UK
CaMKII ab52476 Rabbit 1:100 1:20000 Abcam; Cambridge, UK
DREAM (FL-214) sc-9142 Rabbit 1:250 1:500 Santa Cruz Biotech, Santa Cruz, CA, USA
Anti-Kir4.1 APC-035 Rabbit 1:1000 – Alomone Labs Ltd., Jerusalem, Israel
Anti-β-actin Sc-47778 Mouse – 1:5000 Santa Cruz Biotech, Santa Cruz, CA, USA
CGRP ab81887 Mouse 1:100 – Abcam; Cambridge, UK
CLR 132 Sheep 1:100 – Merck & Co., Inc
RAMP1 844 Goat 1:100 – Merck & Co., Inc
Abbreviations: CaMKII calcium calmodulin-dependent protein kinase II; CGRP calcitonin gene-related peptide; CLR calcitonin receptor-like receptor; DREAM downstream
regulatory element antagonist modulator; ERK1/2 extracellular signal-regulated kinase 1/2; Kir4.1 inwardly rectifying potassium channel; MAPK mitogen-activated protein
kinase; NF-κB nuclear factor kappa B; RAMP1 receptor activity modifying protein 1; SAPK/JNK stress-activated protein kinase/c-jun N-terminal kinase
Table 2 Secondary antibodies used for immunohistochemistry (IH) and Western blotting (WB)
Conjugate and host Against Dilution Source
IH
FITC (goat) Anti-rabbit 1:100 Cayman Chemical, Ann Arbor, MI, USA
Texas-Red (donkey) Anti-rabbit 1:200 Jackson Immunoresearch, West Grove, PA, USA
DyLight 549 (donkey) Anti-mouse 1:200 Jackson Immunoresearch, West Grove, PA, USA
DyLight 488 (donkey) Anti-sheep 1:200 Jackson Immunoresearch, West Grove, PA, USA
Alexa 488 (donkey) Anti-goat 1:400 Invitrogen, La Jolla, CA, USA
WB
HRP-conjugated Anti-rabbit 1:2000 Cell Signaling Technology, Danvers, MA, USA
HRP-conjugated Anti-mouse 1:2000 Cell Signaling Technology, Danvers, MA, USA
Abbreviations: FITC fluorescein isothiocyanate; HRP horseradish peroxidase
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Fig. 2 Hematoxylin-Eosin staining of trigeminal ganglia from control (fresh), inflammatory (2 or 10 days post-CFA) and treated (KYNA and
KYNAA2) groups. a Neurons of different size, surrounded by SGCs, were found. b-f As a result of inflammation, perineurium thickening (arrows)
and sterile abscess (asterisk) were present. Inserts show higher magnification of the neurons surrounded by SGCs. In b-f, the inserts show abscesses
with polymorphonuclear cells and macrophages. Insert scale bars 50 μm
Fig. 3 pERK1/2 immunohistochemistry of trigeminal ganglia from control (fresh), inflammatory (2 or 10 days post-CFA) and treated (KYNA and
KYNAA2) groups. a In fresh trigeminal ganglia, pERK1/2 positive nuclei with nucleoli (thin arrows) and only nucleoli (thin arrow heads) were seen.
b-c At 2 and 10 days post-CFA injection, pERK1/2-immunoreactive SGCs (thick arrows) were present. In addition, at 10 days post-CFA injection,
some positive nuclei and nucleoli were also found (thin arrow). d-e KYNA and KYNAA2 abolished the pERK1/2-positivity in the SGCs (thick
arrowheads) at 2 days. f After 10 days KYNA-treatment, both negative SGCs (thick arrowhead) and positive SGCs (thick arrow) were seen.
Insert scale bars 50 μm
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addition, increased pERK1/2 immunoreactivity was ob-
served in neuronal nuclei and nucleoli at 10 days (Fig. 3c).
Treatment with KYNA and KYNAA2 abolished the
pERK1/2 immunoreactivity in the SGCs at 2 days
(Fig. 3d–e). The effect of KYNA-treatment was only par-
tial at 10 days, with both pERK1/2-positive and pERK1/
2-negative SGCs (Fig. 3f ). pERK1/2 expression was not
detected in the cytoplasm of neurons.
pp38
In fresh TG, pp38 immunoreactivity was found in neuronal
nuclei (Fig. 4a). At 2 and 10 days post-CFA injection, pp38
positive SGCs and neuronal nuclei were found, in
addition to some stained small- to medium-sized neu-
rons (Figs. 4b–c).
Both KYNA and KYNAA2 decreased the nuclei immu-
noreactivity at 2 days post-CFA injection. At 2 days
KYNAA2, but not the KYNA treatment, reduced CFA-
induced SGC immunoreactivity (Figs. 4d–e). At 10 days
post-CFA injection, KYNA-treatment attenuated pp38 im-
munoreactivity in the SGCs but did not influence the pp38
immunoreactivity in the nuclei (Fig. 4f). To confirm that
the SGCs were pp38 immunoreactive, double staining with
the SGCs specific Kir4.1 was performed. The stainings re-
vealed co-localization between pp38 and Kir4.1 in the SGCs
(Figs. 4b, c, e, f inserts).
pSAPK/JNK
We found pSAPK/JNK immunoreactive SGCs in all six
groups (Additional file 1: Figures S1a–f ). At 2 days post-
CFA injection, some homogenously stained neurons
were seen in addition to the positive SGCs (Additional
file 1: Figure S1b, arrow head). These immunoreactive
neurons were not found in any of the other groups. To
identify the SGC specificity, double staining with the
SGC specific Kir4.1 was performed. Indeed, co-
localization between pSAPK/JNK and Kir4.1 was seen
(Additional file 1: Figures S1g-i).
NF-κB
NF-κB immunoreactive neuronal nuclei were found in
fresh TG (Fig. 5a). At 2 and 10 days post-CFA injection,
all neurons showed increased NF-κB immunoreactivity,
both in the cytoplasm and in nuclei (Figs. 5b–c). At two
days, KYNA- or KYNAA2-treatment did not alter the
NF-κB neuronal immunoreactivity (Figs. 5d–e). At
Fig. 4 pp38 immunohistochemistry of trigeminal ganglia from control (fresh), inflammatory (2 or 10 days post-CFA) and treated (KYNA and
KYNAA2) groups. a In fresh trigeminal ganglia, pp38 immunoreactive neuronal nuclei (thin arrow) were found. b At 2 days post-CFA injection,
positive neuronal nuclei (thin arrow), a few neurons (thin arrowhead) and many SGCs (thick arrow) were present. c At 10 days, positive neuronal
nuclei (thin arrow) and many SGCs (thick arrow) were found. In addition, some positive small- to medium sized neurons were found. d At 2 days
post-CFA injection, KYNAA2 abolished the pp38-immunoreactivity in the SGCs (thick arrowheads) and in the small- and medium sized neurons.
e At 2 days after KYNA-treatment many pp38-immunoreactive SGCs (thick arrow) were seen. No immunoreactivity was observed in the small- and
medium sized neurons. f At 10 days, KYNA-treatment decreased the number and intensity of immunoreactive SGCs. Inserts show double staining with
Kir4.1 (green) and pp38 (red) and the merged images with DAPI (nuclei staining), which revealed co-localization at 2 and 10 days post-CFA injection,
and after KYNA-treatment at 2 and 10 days (b, c, e, f inserts). Insert scale bars 50 μm
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10 days, KYNA-treatment abolished the presence of
neuronal NF-κB immunoreactivity. The immunoreactiv-
ity was similar to fresh animals, suggesting a strong
effect of KYNA at 10 days (Fig. 5f ).
CaMKII
In fresh TG, the intensity of the staining varied from
negative neurons to intense, homogenously stained
CaMKII immunoreactive neurons of varying size
(Additional file 2: Figure S2a). At 2 and 10 days post-
CFA injection as well as in the KYNA and KYNAA2-
treated groups, most of the neurons were immunore-
active (Additional file 2: Figures S2b–f ). CaMKII
expression was not detected in the SGCs or in the
nuclei of the neurons.
DREAM
We found homogenous DREAM immunoreactivity in
the cytoplasm of some neurons and in the neuronal nu-
clei of fresh TG (Additional file 3: Figure S3a). Two or
10 days post-CFA injection, inflammation resulted in in-
creased DREAM expression in most of the neurons
(Additional file 3: Figures S3b-c). KYNA- or KYNAA2-
treatment did not show any changes in the expression
(Additional file 3: Figures S3d–f ).
Summary of pERK1/2, pp38, and NF-κB, immunohis-
tochemistry results are schematically shown in Fig. 6.
Double immunohistochemistry
pERK1/2 and CLR/RAMP1
At two days post-CFA injection, double immunohisto-
chemistry was performed with pERK1/2 and the CGRP
receptor components CLR and RAMP1. We observed
that pERK1/2 co-localized with CLR and RAMP1 in the
SGCs (Figs. 7, 8).
NF-κB and CGRP
Double immunohistochemistry with NF-κB and CGRP
was carried out in the TG at 2 days post-CFA injection.
In our hands, co-localization was found in some of the
small- and medium sized neurons (Fig. 9).
Interactions
Figure 10 attempts to illustrate a suggested interaction
between CGRP and its receptor components, pERK1/2
and NF-κB. At two days post-CFA injection in the tri-
geminal ganglion the pERK1/2 immunoreactive SGCs
induce the activation of NF-κB in the small- and
medium sized neurons, which co-localize with CGRP.
Presumably, the activation of NF-κB promotes the re-
lease of CGRP from small-and medium sized neurons.
The released CGRP displays its effect on SGCs and large
neurons, which contain the CGRP receptor components
CLR and RAMP1.
Fig. 5 NF-κB staining of trigeminal ganglia from control (fresh), inflammatory (2 or 10 days post-CFA) and treated (KYNA and KYNAA2) groups.
a In fresh trigeminal ganglia, NF-κB immunoreactive neuronal nuclei (thin arrow) were found. b-c At 2 and 10 days post-CFA injection, all of the
neurons showed increased NF-κB intensity (thick arrow), out of them a few small- and medium-sized neurons seemed to be positive (thin arrowhead).
Some of the neuronal nuclei showed higher NF-κB-expression (thin arrow). d-e KYNAA2- and KYNA-treatment at 2 days did not alter the expression of
NF-κB; thick arrow points at intense neuronal NF-κB expression, some of these immunoreactive neurons were identified as small- to medium sized
neurons (arrow head), thin arrow points at immunoreactive neuronal nuclei. f After 10 days KYNA-treatment, the staining was similar to the staining of
the healthy group
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Fig. 6 Schematic summary of pERK1/2, pp38 and NF-κB findings
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Western blot
The protein level of pERK1/2, pp38, pSAPK/JNK,
CaMKII, NF-κB and DREAM in TG was measured by
Western blot. Densitometric analyses confirmed that
pERK1/2 was significantly enhanced at10 days post-
CFA injection (p = 0.016). This level was normalized
in the 10 days KYNA treated animals (p = 0.008)
(Fig. 11). There was a significant increase observed at
2 days post-CFA injection in the pp38 level (p = 0.011).
This level of phosphorylated p38 was significantly
lower in animals treated with KYNA (p = 0.027) or
KYNAA2 (p = 0.004) two days after the CFA injection
(Fig. 11). There were no significant changes in
pSAPK/JNK, NF-κB, CaMKII and DREAM protein
levels (data not shown). Levels of β-actin confirmed
equal loading of protein samples.
Discussion
This is the first study that examines in details the effects
of KYNA and KYNAA2 on the expressional alterations
in inflammation-related molecules in the mandibular
part of the TG (Fig. 1) after administration of CFA into
the TMJ. We found at day 2 and at day 10 post-CFA in-
jection, an increased expression of pERK1/2 and pp38 in
neurons or SGCs, while only neurons showed an
increased NF-κB and CaMKII immunoreactivity. Treat-
ment with the glutamate modulators KYNA and its der-
ivate KYNAA2 reduced or normalized the pERK1/2,
pp38 and NF-κB immunoreactivity. The findings suggest
that local inflammation of the TMJ, induced by CFA, re-
sults in an inflammation response in the TG where the
TMJ sensory fibers have their cell bodies. Interestingly,
this involves both neurons and SGCs which represent
together an anatomical (Fig. 2a, insert) and functional
unit [46].
It has been already demonstrated, using SGC detecting
glial fibrillary acidic protein (GFAP) immunohistochem-
istry that 24 and 72 h post-saline injections into TMJ
have the same inflammatory effect as the ones seen in
the contralateral CFA injected TMJ tissue, i.e. few GFAP
immunoreactive SGCs. On the other hand, 24 and 72 h
post-CFA treated ipsilateral side showed a significant in-
crease of GFAP immunoreactive SGCs [42]. Moreover,
similar results were found during the measurement of
the Evans’ Blue dye extravasation in the TMJ. Saline in-
jection into TMJ resulted in the same inflammatory effect
as was found in the contralateral side of the CFA-
injection. The ipsilateral TMJ displayed 5–8 times higher
Evans’ Blue concentration compared to saline injected ani-
mals [42]. For these reasons, we used fresh animals as
controls in order to achieve the normal protein expression
and to compare this expression to the CFA-injected ipsi-
lateral side, and furthermore to evaluate possible effects of
KYYNA and KYNAA2 treatments.
The CFA injection method is a widely accepted in-
flammatory model of the trigeminal activation [47].
The proposed mechanism of this method is that after
the CFA stimulation the number of macrophages in-
creases dramatically in the TG around the neurons
[48], which release cytokines, MAPKs and other me-
diators [47]. The increased release of MAPK signaling
proteins takes part in the process of the peripheral
sensitization of the primary nociceptive neurons in
the sensory ganglia [10, 47, 49].
Fig. 7 Double immunohistochemistry with pERK1/2 and CLR at 2 days post-CFA injection, which revealed co-localized pERK1/2 and CLR in the
SGCs (arrows)
Fig. 8 Double immunohistochemistry with pERK1/2 and RAMP1 at 2 days post-CFA injection, which revealed co-localized RAMP1 and pERK1/2 in
the SGCs (arrows)
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pERK1/2, pp38 and pSAPK/JNK
SGCs form a tight envelope around neurons (Fig. 2a),
coupled by gap junctions, in sensory ganglia. Many stud-
ies have investigated SGC morphology and physiology,
giving the subject for numerous reviews [1, 2, 50–54].
The expression of Kir4.1, glutamate recycling compo-
nent, the glutamate-aspartate transporter and P2Y4 me-
tabotropic purinergic receptors have been shown in
SGCs in the TG [55]. Silencing the Kir4.1 expression in
the TG results in spontaneous and evoked pain
sensation, suggesting its importance in pain [56]. In-
crease in SGCs S100B expression 2 h after capsaicin in-
jection into the TMJ and activation of p38 after NO-
proton or TNF-α stimulation have been demonstrated
[17, 57, 58]. Garrett and Durham [59] injected CFA or
capsaicin into the TMJ, which resulted in increased pro-
tein expression of connexin26 in the SGCs in the TG.
Cady et al. [60] showed pERK1/2 activation in the SGCs
2–24 h after CGRP injection into the TMJ. In the
present study we show the time-related activation of
Fig. 9 Double immunohistochemistry with NF-κB and CGRP at 2 days post-CFA injection. Thick arrowhead point at a CGRP-positive neuron, thin
arrow at a double-stained CGRP and NF-κB neuron
Fig. 10 At 2 days post-CFA injection in the trigeminal ganglion the pERK1/2 immunoreactive SGCs induce the activation of NF-κB in the small- and
medium sized neurons, which co-localize with CGRP. Presumably, the activation of NF-κB promotes the release of CGRP from small- and medium sized
neurons. The released CGRP displays its effect on SGCs and large neurons, which contain the CGRP receptor components, the CLR and RAMP1 in the
trigeminal ganglion
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Fig. 11 Western blot. a pERK1/2 and pp38 protein expression in rat trigeminal ganglion in healthy conditions, at 2 and 10 days post-CFA injection
and after treatment with KYNA or KYNAA2. The protein levels were examined by Western blot. b Graphical representation of optical density ratio
of pERK1/2 and pp38 protein normalized to β-actin. Values are mean ± S.D. (n = 6) (*p≤ 0.05, **p ≤ 0.005)
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MAPKs (pERK1/2, pp38) in SGCs post-CFA injection,
which is diminished after KYNA and/or KYNAA2 treat-
ment (Figs. 3 and 4). Together, these data suggest that
SGCs play a role in spontaneous and evoked pain sensa-
tion, and inflammation-induced peripheral sensitization in
the TG.
To confirm results obtained from immunohisto-
chemistry, Western blot was used. Analyses confirmed
that pERK1/2 was significantly enhanced at 10 days
post-CFA injection (p = 0.016). This level was normal-
ized in the 10 days KYNA treated animals (p = 0.008)
(Fig. 11). In addition, there was a significant increase
observed at 2 days post-CFA injection in the pp38
level (p = 0.011). This level of phosphorylated p38
was significantly lower in animals treated with
KYNA (p = 0.027) or KYNAA2 (p = 0.004) two days
after the CFA injection (Fig. 11).
NF-κB, CaMKII and DREAM
The MAPKs are activated by inflammatory mediators and
initiate the expression of transcription factors, such as NF-
κB [19–21], while CaMKII and DREAM are involved in
nociception and pain transmission [24, 25, 27, 28]. Our re-
sults showed a strong NF-κB activation in the neuronal
cytoplasm, both 2 and 10 days after CFA-stimulation
(Figs. 5b–c). This suggests that the regulation of transcrip-
tion factor is a time-consuming process. In this inflamma-
tory model no sharp differences were observed in the
glial or neuronal expression of CaMKII and DREAM
(Additional files 2 and 3: Figures S2-3). The stimula-
tion by inflammatory mediators at the terminals of
unmyelinated nerve fibers results in activation of
MAPKs and transcription factors in the trigeminal
system.
CGRP
Previous studies suggest that glutamate is present in the
trigeminovascular system [61–63]. Eftekhari et al. has
demonstrated that glutamate and CGRP are mostly
expressed in separate neurons in the rat and rhesus TG
[64]. This suggests that the trigeminal neurons that
express CGRP do not contain glutamate as a co-
transmitter. Furthermore, in a double-staining of glu-
tamate and CGRP receptor components, the CLR or the
RAMP1 showed a co-localization with glutamate in the
trigeminal neurons of rat and rhesus [64]. This opens up
the possibility of interaction between the glutamate sys-
tem and CGRP receptors.
At two days post-CFA injection in the TG the
pERK1/2 immunoreactive SGCs induce the activation
of NF-κB in the small- and medium sized neurons,
which co-localize with CGRP. Presumably, the activation
of NF-κB promotes the release of CGRP from small- and
medium sized neurons. The released CGRP displays its
effect on SGCs and large neurons, which contain the
CGRP receptor components, the CLR and RAMP1 in the
TG (Fig. 10). As CLR and RAMP1 co-localize with
pERK1/2 in the SGCs (Fig. 7–8), this process may cause a
self-amplifying cycle. These observations and the raised
hypothesis initiate the need of further investigations.
In TMJ inflammation, there is a varying degree of in-
crease in the concentrations of different inflammatory
mediators (such as CGRP, nerve growth factor,
interleukin-1β and TNF-α) in the TG [4]. CFA stimulation
of the TMJ results in a significantly higher trigeminal Fos
protein expression than the stimulation of the perioral
skin as there is heavy innervation of the TMJ by unmyelin-
ated nerve endings [65]. An immunohistochemical study
revealed that the NR1 subunit of the NMDA receptor is
expressed in all sized of the neurons in the TG, while the
NR2 subunit is mainly in the small sized neurons and in
the SGCs [5]. It has been also reported that NMDA re-
ceptor antagonists (DL-2-amino-5-phosphonovaleric
acid and Ifenprodil) blocked CFA-induced mechanical
hypersensitivity of the TMJ region and the constitutive
expression of NMDA receptor subunits in the TG [5].
The kynurenine pathway of tryptophan metabolism
produces several neuroactive by-products (such as
KYNA, xanthurenic acid, cinnabarinic acid and quinolinic
acid), acting on both NMDA and metabotropic glutam-
ate receptors [37, 66]. KYNA is an endogenous excitatory
amino acid receptor blocker. KYNA acts as a potent
NMDA receptor antagonist, as its primary site of action
is the strychnine-insensitive glycine site of the NMDA
receptor at low micromolar concentrations [36]. Hilmas
et al. [38] demonstrated that KYNA non-competitively
and voltage independently inhibits alpha7 nicotinic
acetylcholine receptors located on pre-synaptic termi-
nals. In addition KYNA is a weak amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) or kainate
sensitive glutamate receptor blocker in micromolar to
millimolar concentrations, while it is able to facilitate
AMPA receptors in nanomolar concentrations [39, 40].
Our findings may suggest a function of KYNA and
KYNAA2, in the used doses, in glutamatergic and
nicotinergic neurotransmission.
Conclusions
The CFA-induced inflammatory model for the TG acti-
vation provided a time-related expression of MAPK
(pERK1/2; pp38) and NF-κB. It involves both the neur-
onal and glial activation, which points the possible
neuron-glia interaction during this process. The admin-
istration of the endogenous NMDA-receptor antago-
nists, KYNA and its derivative KYNAA2, resulted in the
inhibition of the induced signaling system of the TG,
which further points the importance of the glutamate re-
ceptors in this mechanism.
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Additional files
Additional file 1: Figure S1. pSAPK/JNK immunohistochemistry of
trigeminal ganglia from control (fresh), inflammatory (2 or 10 days post-CFA)
and treated (KYNA and KYNAA2) groups. a-f pSAPK/JNK immunoreactive
SGCs were found in all six groups. No difference was noticed between the
groups except for some homogenously stained neurons at 2 days post-CFA
(b). g-i To identify the SGC specificity, double staining with the SGC specific
Kir4.1 was performed. Indeed, co-localization between pSAPK/JNK and Kir4.1
was seen. Insert scale bars 50 μm. (JPG 10261 kb)
Additional file 2: Figure S2. CaMKII immunohistochemistry of trigeminal
ganglia from control (fresh), inflammatory (2 or 10 days post-CFA) and
treated (KYNA and KYNAA2) groups. a In fresh trigeminal ganglia, the
intensity of the staining varied from negative neurons to intense,
homogenously stained CaMKII immunoreactive neurons of varying
size (thin arrowhead - intensely stained neuron; thick arrow - neurons
with lesser expression; thin arrow - negative neurons). b-f At 2 and 10 days
post-CFA injection as well as in the KYNA and KYNAA2-treated groups, most
of the neurons were immunoreactive. CaMKII expression was not detected
in the SGCs or in the nuclei of the neurons. Insert scale bars 50 μm.
(JPG 4521 kb)
Additional file 3: Figure S3. DREAM immunohistochemistry of trigeminal
ganglia from control (fresh), inflammatory (2 or 10 days post-CFA) and treated
(KYNA and KYNAA2) groups. a In fresh trigeminal ganglia homogenous
DREAM immunoreactivity was found in the cytoplasm of some neurons
(arrow head) and in the neuronal nuclei (thin arrow). b-c Two or 10 days
post-CFA injection, inflammation resulted in increased DREAM expression in
most of the neurons (arrow head). d-f KYNA- or KYNAA2-treatment did not
show any changes in the expression. Insert scale bars 50 μm. (JPG 5002 kb)
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